PRIMA BIOMED LTD
Australian Cancer Treatment Company

ASX/Media Release (Code: PRR)
12 September 2011

PATIENT ENROLMENT FOR CVac PHASE IIb TRIAL COMPLETE

Australian health care company Prima BioMed Ltd (ASX: PRR) (Prima) is pleased to announce that it has completed full patient enrolment for its Phase IIb Trial for the CVac™ immunotherapy ovarian cancer vaccine.

Prima commenced enrolment into the 60 patient trial in 23rd July 2010. In February this year, the Company announced that the first patient cohort, of seven patients, in the CVac™ Phase IIb Trial had successfully completed the first treatment with the vaccine, with no therapy related adverse effects.

As a result, the Data Safety Monitoring Board confirmed that the Phase IIb Trial was safe to proceed, and Prima commenced patient enrolment (a further 54 patients) into the randomised component of the Phase IIb Trial.

The Company is delighted to report that patient enrolment into the trial, with a patient group who meet the trial's eligibility criteria, is now compete. The trial is being conducted in five premier sites in Australia and 15 sites across the US. These include the Stanford Medical Centre, under the leadership of world-leading gynealogical expert Dr Jonathan Berek, the Fred Hutchinson Cancer Center in Seattle and the Peter MacCallum Cancer Center in Melbourne.

The level of patient uptake into the trial represents a major validation of the trial's purpose, and Prima's end goal for CVac™ to provide a viable, commercially available treatment option for ovarian cancer patients globally.

The Phase IIb Trial design is a randomised and open label trial, comparing patients are in remission after 1st/2nd line active treatment with CVac™ to observed standard of care. The primary objectives of the trial are to confirm the manufacturing comparability of multiple sites, potency assay, safety of CVac™ and compare disease progression (PFS) between CVac™ and the control group.

To assess PFS, clinical assessments will be performed every four weeks, and imaging with computed tomography (CT) or magnetic resonance imaging (MRI) will be performed every 12 weeks - until progression or withdrawal of the patient from trial. Initial safety data is expected in [date], after completion of the treatment phase. Initial PFS data is expected in [date], after all patients have completed two years of observation.

The aim of the trial is to augment the promising efficacy data generated by previous studies, including the phase IIa pilot study completed in 2007, on 28 patients.

Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
www.primabiomed.com.au
ABN: 90 009 237 889

Prima BioMed CEO Martin Rogers said: “The completion of enrolment into the CVac™ Phase IIb Trial represents an important milestone for the Company in our pathway towards commercialisation for CVac™. We have been delighted with the level of interest in the trial across our high calibre trial sites in the US and Australia, and look forward to delivering the PFS trial results in due course.”

ENDS

For further information please contact:

Martin Rogers
Chief Executive Officer
Prima BioMed
Ph: +61 2 9276 1242
E: martin.rogers@primabiomed.com.au
Website: www.primabiomed.com.au

Mr James Moses
Investor and Media Relations
Mandate Corporate
Ph: +61 (0) 420 991 574
E: james@mandatecorporate.com.au

About CVac™ Ovarian Cancer Treatment

CVac™ is Prima BioMed’s core product. It is a vaccine therapy treatment for ovarian cancer sufferers that is administered post-surgery and post-chemotherapy to delay the relapse and control the metastases of the cancer. There is a large un-met medical need for new treatments for ovarian cancer which has a very high morbidity rate, and there are currently no maintenance-based therapy products commercially available.

The Company has commenced its Phase IIb Trial for CVac™ with the US FDA and plans to commence a Phase III Clinical Trial for CVac™ in Europe and the US this year. The Phase IIb and Phase III Trials aim to further confirm the ability of CVac™ to reduce the instance of relapse in ovarian cancer patients, control the metastases of the cancer and increase the life expectancy of patients.

Prima’s ultimate goal is to commercialise CVac™ into the multi-billion dollar global pharmacy oncology market. The global market for ovarian cancer therapeutics was valued at US$2.1b in 2007 and was estimated to have grown to US$3.6b in 2010.

Regulatory approval and commercialization of CVac™ is the core focus for Prima.

About Prima BioMed

Prima BioMed is an ASX listed Australian health care company. The Company is focused on technologies in the fields of cancer immunotherapy and immunology.

Prima’s lead product is CVac™ ovarian cancer therapy treatment. It has completed two successful clinical trials and is progressing toward eventual commercialization in the United States, Australia, Europe, and globally.

The Company’s broader, long term goal is to develop commercial cancer treatment technologies and programs for global markets.